Alpha 2.0
Login Register
» Authors » Ryoichi Muraoka

Ryoichi Muraoka

Explore the profile of Ryoichi Muraoka including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 45
Followers 0
Related Specialties
Endocrinology
Pathology
Nephrology
Top 10 Co-Authors
Ryo Okazaki
Yoshiki Nishizawa
Masayuki Maehara
Toshitsugu Sugimoto
Daisuke Inoue
Mitsuharu Osawa
Yukihide Iwamoto
Takashi Shigematsu
Shinya Kawahara
Takashi Umemura
Published In
J Bone Miner Metab
Calcif Tissue Int
Bone Rep
BMC Nephrol
Affiliations
Soon will be listed here.
Recent Articles
1.
Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial
Mawatari T, Ikemura S, Matsui G, Iguchi T, Mitsuyasu H, Kawahara S, et al.
Bone Rep . 2020 May; 12:100275. PMID: 32462056
Background: Risedronate increases bone mineral density (BMD) and reduces fracture risk, but treatment response may depend on the baseline state of bone turnover. Data regarding the selection of therapeutic drugs...
2.
Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis
Okazaki R, Muraoka R, Maehara M, Inoue D
J Bone Miner Metab . 2018 May; 37(1):185-197. PMID: 29737412
Factors associated with an inadequate response (IR) to bisphosphonates have been reported in many countries, but not in Japan, where the approved dose is half the global dose. We analyzed...
3.
Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y
BMC Nephrol . 2017 Feb; 18(1):66. PMID: 28201994
Background: The clinical effect of bisphosphonate treatment has not been clearly evaluated by kidney function in Japanese Chronic Kidney Disease (CKD) patients with osteoporosis. This study analyzed the data from...
4.
Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice
Soen S, Umemura T, Ando T, Kamisaki T, Nishikawa M, Muraoka R, et al.
J Bone Miner Metab . 2016 Aug; 35(4):419-427. PMID: 27565972
Currently, the only available evidence for the efficacy of once-weekly 17.5 mg risedronate in preventing vertebral fractures was obtained in a 48-week study in Japan. We performed a 156-week prospective,...
5.
Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan
Inoue D, Muraoka R, Okazaki R, Nishizawa Y, Sugimoto T
Calcif Tissue Int . 2015 Oct; 98(2):114-22. PMID: 26466937
Many osteoporotics have comorbid diabetes mellitus (DM), hypertension (HT), and dyslipidemia (DL). However, whether such comorbidities alter response to anti-osteoporotic treatment is unknown. We did post hoc analyses of combined...